Drug Information

General Information
Drug ID
DR01729
Drug Name
Monocrotaline
Synonyms
monocrotaline; Crotaline; 315-22-0; Monocrotalin; (-)-Monocrotaline; NCI-C56462; NSC 28693; CCRIS 416; CHEBI:6980; HSDB 3513; Retronecine cyclic 2,3-dihydroxy-2,3,4-trimethylglutarate; A 6080; BRN 0048732; (13-alpha,14-alpha)-14,19-Dihydro-12,13-dihydroxy-20-norcrotalanan-11,15-dione; UNII-73077K8HYV; MLS002153902; DTXSID9020902; 14,19-Dihydro-12,13-dihydroxy-20-norcrotolanan-11,15-dione; 73077K8HYV; 20-Norcrotalanan-11,15-dione, 14,19-dihydro-12,13-dihydroxy-, (13alpha,14alpha)-; (3R,4R,5R,13aR,13bR)-4,5-dihydroxy-3,4,5-trimethyl-4,5,8,10,12,13,13a,13b-octahydro-2H-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3H)-dione; NCGC00164256-01; 12-beta,13-beta-Dihydroxy-12-alpha,13-alpha,14-alpha-trimethylcrotal-1-enine; 14,19-Dihydro-12,13-dihydroxy(13-alpha,14-alpha)-20-norcrotalanan-11,15-dione; (2,3,4-gh)pyrrolizine-2,6(3H)-dione, (4,5,8,10,12,13,13a,13b)-octahydro-4,5-dihydroxy-3,4,5-trimethyl-2H-(1,6)dioxacycloundecino-; 4-27-00-06660 (Beilstein Handbook Reference); DTXCID50902; 20-Norcrotalanan-11,15-dione, 14,19-dihydro-12,13-dihydroxy-, (13-alpha,14-alpha)-; 2H-(1,6)Dioxacycloundecino(2,3,4-gh)pyrrolizine-2,6(3H)-dione, 4,5,8,10,12,13,13a,13b-octahydro-4,5-dihydroxy-3,4,5-trimethyl-, (3R,4R,5R,13aR,13bR)-; 2H-[1,6]Dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3H)-dione, 4,5,8,10,12,13,13a,13b-octahydro-4,5-dihydroxy-3,4,5-trimethyl-, (3R,4R,5R,13aR,13bR)-; SR-01000838886; NSC-28693; 20-Norcrotalanan-11,15-dione, 14,19-dihydro-12,13-dihydroxy-, (13.alpha.,14.alpha.)-; CAS-315-22-0; Prestwick_338; Spectrum_001224; Prestwick0_000603; Prestwick1_000603; Prestwick2_000603; Prestwick3_000603; Spectrum2_000906; Spectrum3_000947; Spectrum4_001057; Spectrum5_001233; MONOCROTALINE [MI]; D0G6AB; MONOCROTALINE [HSDB]; MONOCROTALINE [IARC]; BSPBio_000506; KBioGR_001354; KBioSS_001704; DivK1c_000959; SCHEMBL164486; SPECTRUM1502252; SPBio_000752; SPBio_002725; BPBio1_000558; CHEMBL521035; MEGxp0_001899; ACon0_000305; ACon1_000179; HMS502P21; KBio1_000959; KBio2_001704; KBio2_004272; KBio2_006840; KBio3_002014; Monocrotaline, analytical standard; NINDS_000959; HMS1569J08; HMS1921P04; HMS2096J08; HMS2235J12; HY-N0750; Tox21_112094; Tox21_201509; Tox21_302874; BDBM50480309; CCG-39621; MFCD00084656; s3812; AKOS015969712; AKOS032962048; Tox21_112094_1; CS-6164; FS-5652; LS-7530; SDCCGMLS-0066675.P001; IDI1_000959; NCGC00179538-01; NCGC00179538-02; NCGC00179538-03; NCGC00256518-01; NCGC00259060-01; NCGC00262539-03; AC-34918; SMR001233251; JACS 72: 158 (1950); Q-100395; SR-01000838886-3; SR-01000838886-4; BRD-K65508953-001-05-5; BRD-K65508953-001-08-9; Q27107379; (13-alpha,14-alpha)-14,19-dihydro-12,13-dihydroxy-20-norcrotolanan-11,15-dione; (1R,4R,5R,6R,16R)-5,6-dihydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.0??,??]hexadec-10-ene-3,7-dione; (1R,4R,5R,6R,16R)-5,6-dihydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.013,16]hexadec-10-ene-3,7-dione; (3R,4R,5R,8a1R,13aR)-4,5-Dihydroxy-3,4,5-trimethyl-4,5,8,8a1,10,12,13,13a-octahydro-2H-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3H)-dione; (3S,4S,5R,13aR)-4,5-dihydroxy-3,4,5-trimethyl-4,5,8,10,12,13,13a,13b-octahydro-2H-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3H)-dione; 109525-74-8; 2H-(1,6)DIOXACYCLOUNDECINO(2,3,4-GH)PYRROLIZINE-2,6(3H)-DIONE, 4,5,8,10,12,13,13A,13B-OCTAHYDRO-4,5-DIHYDROXY-3,4,5-TRIMETHYL-, (3R-(3R*,4R*,5R*,13AR*,13BR*))-; rel-(3R,4R,5R,8a1R,13aR)-4,5-Dihydroxy-3,4,5-trimethyl-4,5,8,8a1,10,12,13,13a-octahydro-2H-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3H)-dione
Drug Type
Small molecular drug
Indication Discovery agent [ICD11: N.A.] Investigative
Structure
3D MOL 2D MOL
Formula
C16H23NO6
Canonical SMILES
CC1C(=O)OC2CCN3C2C(=CC3)COC(=O)C(C1(C)O)(C)O
InChI
InChI=1S/C16H23NO6/c1-9-13(18)23-11-5-7-17-6-4-10(12(11)17)8-22-14(19)16(3,21)15(9,2)20/h4,9,11-12,20-21H,5-8H2,1-3H3/t9-,11+,12+,15+,16-/m0/s1
InChIKey
QVCMHGGNRFRMAD-XFGHUUIASA-N
CAS Number
CAS 315-22-0
Pharmaceutical Properties Molecular Weight 325.36 Topological Polar Surface Area 96.3
Heavy Atom Count 23 Rotatable Bond Count 0
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 7
XLogP
-0.7
PubChem CID
9415
ChEBI ID
CHEBI:6980
DT(s) Transporting This Drug OCT-1 Transporter Info Organic cation transporter 1 Substrate [1]
OCT-2 Transporter Info Organic cation transporter 2 Substrate [1]
Drug-Transporter Activity Data
Drug-Transporter Activity Data OCT-1 Transporter Info Km = 109.1 microM Human embryonic kidney cells (HEK293)-OCT1 [1]
OCT-2 Transporter Info Km = 64.7 microM Human embryonic kidney cells (HEK293)-OCT2 [1]
References
1 An in vitro study on interaction of anisodine and monocrotaline with organic cation transporters of the SLC22 and SLC47 families. Chin J Nat Med. 2019 Jul;17(7):490-497.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.